DBDavid D. Blaney

David D. Blaney

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David D. Blaney has a total of 316 co-authors. Here are the top co-authors by number of shared publications:

  • Jay E. Gee

    Bacterial Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention

    12 shared publications
  • Alex R. Hoffmaster

    Bacterial Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia; Universidade de Fortaleza (UNIFOR), Fortaleza, Brazil; School of Pathology and Laboratory Medicine, University of Western Australia, Western Australia, Australia

    4 shared publications
  • Alex R. Hoffmaster

    Bacterial Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4018, USA

    4 shared publications
  • Cari A. Beesley

    Bacterial Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4018, USA

    4 shared publications
  • Henry T. Walke

    Bacterial Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia; Universidade de Fortaleza (UNIFOR), Fortaleza, Brazil; School of Pathology and Laboratory Medicine, University of Western Australia, Western Australia, Australia

    4 shared publications
  • Mindy Glass Elrod

    Bacterial Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention

    4 shared publications

Latest Publications

  • Open Access

    Occupational Laboratory Exposures to Burkholderia pseudomallei in the United States: A Review of Exposures and Serological Monitoring Data, 2008–2024

    by Brian T. Richardson, Mindy G. Elrod, Katherine M. DeBord, Caroline A. Schrodt, Julie M. Thompson, Tina J. Benoit, Lindy Liu, Julia K. Petras, David Blaney, Jay E. Gee, et al.

    Infection with Burkholderia pseudomallei, the causative agent of melioidosis, is uncommon in the United States (U.S.), leading to delays in pathogen identification and clinical diagnosis which can often lead to laboratory exposures. The indirect hemagglutination assay (IHA) is the primary serological test for confirming exposure to B. pseudomallei. In the U.S., a titer of ≥1:40 suggests exposure to B. pseudomallei or a closely related species, and a 4-fold rise in IHA titer ≥1:40 with clinically compatible illness is considered diagnostically probable. A retrospective analysis of 160 voluntarily reported laboratory exposure events to B. pseudomallei across 29 U.S. jurisdictions and 5 countries between 2008–2024 was conducted. This analysis included post-exposure management data and IHA results for 855 exposed laboratory personnel who had serological monitoring performed at the U.S. Centers for Disease Control and Prevention (CDC). Among exposed laboratory personnel, 105 (12%) had a seropositive titer. Of these, ninety-one (87%) laboratory personnel remained seropositive (≥1:40) at their last IHA test. Five (1%) people had a 4-fold rise in titers, though none developed melioidosis. This report underscores the need for prospective studies to evaluate seropositive laboratory personnel and to update risk guidance for laboratory exposures in non-endemic areas.


  • Open Access

    Ebola Virus Disease Outbreaks: Lessons Learned From Past and Facing Future Challenges

    by Zygmunt Dembek, Steven Hadeed, Bersabeh Tigabu, Kierstyn Schwartz-Watjen, Michael Glass, Michelle Dressner, Dianne Frankel, David Blaney, Thomas G Eccles Iii, Tesema Chekol, et al.

    Introduction: The purpose of this review is to examine African Ebola outbreaks from their first discovery to the present, to determine how the medical and public health response has changed and identify the causes for those changes. We sought to describe what is now known about the epidemiology and spread of Ebola virus disease (EVD) from the significant outbreaks that have occurred and outbreak control methods applied under often challenging circumstances. Given the substantial role that the U.S. Government and the U.S. DoD have played in the 2014 to 2016 West African Ebola outbreak, the role of the DoD and the U.S. Africa Command in controlling EVD is described. Materials and Methods: A descriptive method design was used to collect and analyze all available Ebola outbreak literature using the PubMed database. An initial literature search was conducted by searching for, obtaining, and reading original source articles on all major global Ebola outbreaks. To conduct a focused search, we used initial search terms “Ebola outbreak,” “Ebola virus disease,” “Ebola response,” “Ebola countermeasures,” and also included each country’s name where Ebola cases are known to have occurred. From the 4,673 unique articles obtained from this search and subsequent article title review, 307 articles were identified for potential inclusion. Following abstract and article review, 45 original source articles were used to compile the history of significant Ebola outbreaks. From this compilation, articles focused on each respective subsection of this review to delineate and describe the history of EVD and response, identifying fundamental changes, were obtained and incorporated. Results: We present known Ebola virus and disease attributes, including a general description, seasonality and location, transmission capacity, clinical symptoms, surveillance, virology, historical EVD outbreaks and response, international support for Ebola outbreak response, U.S. DoD support, medical countermeasures supporting outbreak response, remaining gaps to include policy limitations, regional instability, climate change, migration, and urbanization, public health education and infrastructure, and virus persistence and public awareness. Conclusions: The health and societal impacts of EVD on Africa has been far-reaching, with about 35,000 cases and over 15,000 deaths, with small numbers of cases spreading globally. However, the history of combatting EVD reveals that there is considerable hope for African nations to quickly and successfully respond to Ebola outbreaks, through use of endemic resources including Africa CDC and African Partner Outbreak Response Alliance and the U.S. Africa Command with greater DoD reachback. Although there remains much to be learned about the Ebola virus and EVD including whether the potential for novel strains to become deadly emerging infections, invaluable vaccines, antivirals, and public health measures are now part of the resources that can be used to combat this disease.


  • Open Access

    Case Report: A Fatal Case of Latent Melioidosis Activated by COVID-19

    by Uday Gulati, Ananya C. Nanduri, Prateek Juneja, David Kaufman, Mindy G. Elrod, Cari B. Kolton, Jay E. Gee, Kristen Garafalo, David D. Blaney

    : Melioidosis, endemic in Southeast Asia and Northern Australia, is an uncommon but frequently fatal opportunistic infection caused by the Gram-negative saprophyte Burkholderia pseudomallei. We describe the first reported case of activation of latent melioidosis concurrent with COVID-19-associated lymphopenia and neutropenia in the setting of poorly controlled diabetes. A 43-year-old HIV-positive, diabetic man presented to the emergency department with persistent chills and progressive dyspnea. He was admitted for hypoxia. Chest X-ray showed bilateral parenchymal infiltrates suspicious for COVID-19. Shortly after admission, he became acutely encephalopathic, had a generalized seizure, and was transferred to the intensive care unit after intubation. Further workup showed severe neutropenia and lymphopenia. The patient received empiric antimicrobial coverage and was found to be severe acute respiratory syndrome coronavirus 2 positive. He deteriorated rapidly with refractory shock and persistent hypoxemia, and died 40 hours after admission. Blood cultures and sputum cultures obtained via bronchoalveolar lavage returned positive for Burkholderia pseudomallei. Given confirmed compliance with antiretrovirals, stable CD4 counts, and no recent foreign travel, the patient likely contracted the B. pseudomallei infection from travel to Southeast Asia many years prior and only became symptomatic after succumbing to severe acute respiratory syndrome coronavirus 2 infection. This case highlights the importance of considering activation of latent opportunistic infections by COVID-19 in immunocompromised patients.


  • Open Access

    Global knowledge gaps in acute febrile illness etiologic investigations: A scoping review

    by Chulwoo Rhee, Grishma A. Kharod, Nicolas Schaad, Nathan W. Furukawa, Neil M. Vora, David D. Blaney, John A. Crump, Kevin R. Clarke

    Acute febrile illness (AFI), a common reason for people seeking medical care globally, represents a spectrum of infectious disease etiologies with important variations geographically and by population. There is no standardized approach to conducting AFI etiologic investigations, limiting interpretation of data in a global context. We conducted a scoping review to characterize current AFI research methodologies, identify global research gaps, and provide methodological research standardization recommendations. Using pre-defined terms, we searched Medline, Embase, and Global Health, for publications from January 1, 2005–December 31, 2017. Publications cited in previously published systematic reviews and an online study repository of non-malarial febrile illness etiologies were also included. We screened abstracts for publications reporting on human infectious disease, aimed at determining AFI etiology using laboratory diagnostics. One-hundred ninety publications underwent full-text review, using a standardized tool to collect data on study characteristics, methodology, and laboratory diagnostics. AFI case definitions between publications varied: use of self-reported fever as part of case definitions (28%, 53/190), fever cut-off value (38·0°C most commonly used: 45%, 85/190), and fever measurement site (axillary most commonly used: 19%, 36/190). Eighty-nine publications (47%) did not include exclusion criteria, and inclusion criteria in 13% (24/190) of publications did not include age group. No publications included study settings in Southern Africa, Micronesia & Polynesia, or Central Asia. We summarized standardized reporting practices, specific to AFI etiologic investigations that would increase inter-study comparability. Wider implementation of standardized AFI reporting methods, with multi-pathogen disease detection, could improve comparability of study findings, knowledge of the range of AFI etiologies, and their contributions to the global AFI burden. These steps can guide resource allocation, strengthen outbreak detection and response, target prevention efforts, and improve clinical care, especially in resource-limited settings where disease control often relies on empiric treatment. PROSPERO: CRD42016035666. Acute febrile illness (AFI) is a common reason for people seeking medical care globally with potentially serious infectious etiologies. However, AFI has no current consensus standardized approach when considered as a syndromic case definition for public health surveillance or research, especially in global settings where AFI treatment is performed with limited diagnostic availability. Therefore, the aim of this review was to describe current methodologies in AFI research, identify gaps in research, and provide recommendations for standardization of AFI research. We screened abstracts and completed full-text reviews on publications found through an extensive search. A total of 190 publications were included in the final review, from which we collected data on study characteristics, methodology, and laboratory diagnostics. These collected data elements allowed us to identify where there were inconsistencies in reporting and investigative methods, which data elements were not regularly collected, and what laboratory testing methods were commonly used. Standardized reporting methods for AFI investigations, along with laboratory testing capacity for multiple pathogens, can improve our knowledge of the causative agents of AFI in certain regions of the world. This can help us determine where resources are needed, how to strengthen outbreak detection and response, and how to improve medical care, especially in regions with limited resources.


  • Differentiating New from Newly Detected: Melioidosis in Yap, Federated States of Micronesia

    by Leisha D. Nolen, Eric Lirow, Jay E. Gee, Mindy G. Elrod, Cari B. Kolton, Lindy Liu, William A. Bower, Marissa K. Person, Maria Marfel, David D. Blaney

    Melioidosis is a bacterial infection caused by exposure to water or soil that contains Burkholderia pseudomallei (Bp). Burkholderia pseudomallei is endemic to many tropical and subtropical areas of the world. In 2013, the first case of melioidosis was recognized in Yap, the Federated States of Micronesia. Six additional cases were identified in the subsequent 3 years. An investigation was initiated to understand the epidemiology of melioidosis in Yap. Serum from family and community members of the identified cases were tested for antibodies to Bp. Archived serum from a 2007 Zika serosurvey were also tested for antibodies to Bp. Sequencing of bacterial isolates was performed to understand bacterial phylogeny. Soil and water were tested for the presence of Bp in the environment by culture and PCR. None of the affected patients had a history of travel to melioidosis-endemic countries. Two of the 34 (5.8%) samples from the field investigation and 67 (11.7%) of the historical samples demonstrated serologic evidence of prior Bp exposure. No Bp were detected from 30 soil or water samples. Genotype analysis showed highly related Bp isolates that were unique to Yap. Melioidosis is likely to be endemic to Yap; however, it has only recently been recognized by the clinical community in country. Further investigation is needed to understand the local sites that harbor Bp and represent the highest risk to the community.


  • Melioidosis is in the Americas: A Call to Action for Diagnosing and Treating the Disease

    by Alfredo G. Torres, Franco E. Montufar, Jay E. Gee, Alex R. Hoffmaster, Mindy G. Elrod, Carolina Duarte-Valderrama, Monica G. Huertas, David D. Blaney

    Melioidosis, a disease caused by the pathogen Burkholderia pseudomallei, is a significant underreported endemic disease found in tropical countries worldwide. Recent studies have demonstrated that human melioidosis cases have been increasingly recognized in the Americas. Therefore, the first Scientific Reunion of Melioidosis in the Americas was organized in Colombia, with the participation of health authorities of 11 Latin American countries and the United States. This report summarizes the topics reviewed during the meeting, including how to identify human infections and properly diagnose them, with the goal of increasing recognition of the disease in the Americas.


  • Open Access

    The Leprosy Post-Exposure Prophylaxis (LPEP) programme: update and interim analysis

    by Peter Steinmann, Arielle Cavaliero, Ann Aerts, Sunil Anand, Mohammad Arif, Sarady Sao Ay, Tin Maung Aye, Tanja Barth-Jaeggi, Nand Lal Banstola, Chuda Mani Bhandari, et al.

    Innovative approaches are required to further enhance leprosy control, reduce the number of people developing leprosy, and curb transmission. Early case detection, contact screening, and chemoprophylaxis currently is the most promising approach to achieve this goal. The Leprosy Post-Exposure Prophylaxis (LPEP) programme generates evidence on the feasibility of integrating contact tracing and single-dose rifampicin (SDR) administration into routine leprosy control activities in different settings. The LPEP programme is implemented within the leprosy control programmes of Brazil, Cambodia, India, Indonesia, Myanmar, Nepal, Sri Lanka and Tanzania. Focus is on three key interventions: tracing the contacts of newly diagnosed leprosy patients; screening the contacts for leprosy; and administering SDR to eligible contacts. Country-specific protocol adaptations refer to contact definition, minimal age for SDR, and staff involved. Central coordination, detailed documentation and rigorous supervision ensure quality evidence. Around 2 years of field work had been completed in seven countries by July 2017. The 5,941 enrolled index patients (89.4% of the registered) identified a total of 123,311 contacts, of which 99.1% were traced and screened. Among them, 406 new leprosy patients were identified (329/100,000), and 10,883 (8.9%) were excluded from SDR for various reasons. Also, 785 contacts (0.7%) refused the prophylactic treatment with SDR. Overall, SDR was administered to 89.0% of the listed contacts. Post-exposure prophylaxis with SDR is safe; can be integrated into the routines of different leprosy control programmes; and is generally well accepted by index patients, their contacts and the health workforce. The programme has also invigorated local leprosy control.


  • Open Access

    Elizabethkingia in Children: A Comprehensive Review of Symptomatic Cases Reported From 1944 to 2017

    by Eric J Dziuban, Jessica L Franks, Marvin So, Georgina Peacock, David D Blaney

    Elizabethkingia species often exhibit extensive antibiotic resistance and result in high morbidity and mortality, yet no systematic reviews exist that thoroughly characterize and quantify concerns for infected infants and children. We performed a review of literature and identified an initial 902 articles; 96 articles reporting 283 pediatric cases met our inclusion criteria and were subsequently reviewed. Case reports spanned 28 countries and ranged from 1944 to 2017. Neonatal meningitis remains the most common presentation of this organism in children, along with a range of other clinical manifestations. The majority of reported cases occurred as isolated cases, rather than within outbreaks. Mortality was high but has decreased in recent years, although neurologic sequelae among survivors remains concerning. Child outcomes can be improved through effective prevention measures and early identification and treatment of infected patients.


  • A Review of Melioidosis Cases in the Americas

    by Tina J. Benoit, David D. Blaney, Thomas J. Doker, Jay E. Gee, Mindy G. Elrod, Dionne B. Rolim, Timothy J. J. Inglis, Alex R. Hoffmaster, William A. Bower, Henry T. Walke

    Melioidosis is a bacterial infection caused by Burkholderia pseudomallei, a gram-negative saprophytic bacillus. Cases occur sporadically in the Americas with an increasing number of cases observed among people with no travel history to endemic countries. To better understand the incidence of the disease in the Americas, we reviewed the literature, including unpublished cases reported to the Centers for Disease Control and Prevention. Of 120 identified human cases, occurring between 1947 and June 2015, 95 cases (79%) were likely acquired in the Americas; the mortality rate was 39%. Burkholderia pseudomallei appears to be widespread in South, Central, and North America.


    • 3 July 2015
      • Vol. 64  (5) , 1-9

    Melioidosis Cases and Selected Reports of Occupational Exposures to Burkholderia pseudomallei--United States, 2008-2013.

    by Tina J Benoit, David D Blaney, Jay E Gee, Mindy G Elrod, Alex R Hoffmaster, Thomas J Doker, William A Bower, Henry T Walke, Centers For Disease Control And Prevention (Cdc)

    Melioidosis is an infection caused by the Gram-negative bacillus Burkholderia pseudomallei, which is naturally found in water and soil in areas endemic for melioidosis. Infection can be severe and sometimes fatal. The federal select agent program designates B. pseudomallei as a Tier 1 overlap select agent, which can affect both humans and animals. Identification of B. pseudomallei and all occupational exposures must be reported to the Federal Select Agent Program immediately (i.e., within 24 hours), whereas states are not required to notify CDC's Bacterial Special Pathogens Branch (BSPB) of human infections. 2008-2013. The passive surveillance system includes reports of suspected (human and animal) melioidosis cases and reports of incidents of possible occupational exposures. Reporting of suspected cases to BSPB is voluntary. BSPB receives reports of occupational exposure in the context of a request for technical consultation (so that the system does not include the full complement of the mandatory and confidential reporting to the Federal Select Agent Program). Reporting sources include state health departments, medical facilities, microbiologic laboratories, or research facilities. Melioidosis cases are classified using the standard case definition adopted by the Council of State and Territorial Epidemiologists in 2011. In follow up to reports of occupational exposures, CDC often provides technical assistance to state health departments to identify all persons with possible exposures, define level of risk, and provide recommendations for postexposure prophylaxis and health monitoring of exposed persons. During 2008-2013, BSPB provided technical assistance to 20 U.S. states and Puerto Rico involving 37 confirmed cases of melioidosis (34 human cases and three animal cases). Among those with documented travel history, the majority of reported cases (64%) occurred among persons with a documented travel history to areas endemic for melioidosis. Two persons did not report any travel outside of the United States. Separately, six incidents of possible occupational exposure involving research activities also were reported to BSPB, for which two incidents involved occupational exposures and no human infections occurred. Technical assistance was not required for these incidents because of risk-level (low or none) and appropriate onsite occupational safety response. Of the 261 persons at risk for occupational exposure to B. pseudomallei while performing laboratory diagnostics, 43 (16%) persons had high-risk exposures, 130 (50%) persons had low-risk exposures, and 88 (34%) persons were classified as having undetermined or unknown risk. A small number of U.S. cases of melioidosis have been reported among persons with no travel history outside of the United States, whereas the majority of cases have occurred in persons with a travel history to areas endemic for melioidosis. If the number of travelers continues to increase in countries where the disease is endemic, the likelihood of identifying imported melioidosis cases in the United States might also increase. Reporting of melioidosis cases can improve the ability to monitor the incidence and prevalence of the disease in the United States. To improve prevention and control of melioidosis, CDC recommends that (1) physicians consider melioidosis in the differential diagnosis of patients with acute febrile illnesses, risk factors for melioidosis, and compatible travel or exposure history; (2) personnel at risk for occupational exposure (e.g., laboratory workers or researchers) follow proper safety practices, which includes using appropriate personal protective equipment when working with unknown pathogens; and (3) all possible occupational exposures to B. pseudomallei be reported voluntarily to BSPB.